Skip to main content
Equibles
VOR logo

VOR · Vor Biopharma Inc. · Metrics

Track VOR — free

Use VOR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VOR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$20.12 +0.56 (+2.89%)
Russell 2000 member Rebalance outlook locked
Market Cap
$1.20B
Shares
61.43M
Volume · Nov 11 120.16K Avg daily vol (3M) 937.34K

VOR metrics

57 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$19.56
Market cap
$1.20B

Price action

23 metrics
Price change (1W)
-1.5%
Price change (30D)
-1.2%
Price change (3M)
-17.1%
Price change (6M)
+18.8%
Price change (YTD)
+49.5%
Price change (1Y)
+4.0%
Trailing year
Price change (5Y)
—
52-week high
$25.10
52-week low
$6.86
Change from 52-week high
-22.1%
Change from 52-week low
+185.1%
Annualized volatility
105.2%
Annualized volatility (3M)
60.2%
Implied volatility (30D)
93.8%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
1.7
RSI (14D)
49.7
Price vs SMA 50
-3.4%
Price vs SMA 200
+12.1%
Avg volume (3M)
937,337
Relative volume
0.4
Average dollar volume
$19.56M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
61.43M

Valuation

12 metrics
P / E (TTM)
0.1
Trailing earnings · reciprocal yield 1,533.0%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
-10.0%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
112.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$177.42M
Net income (TTM)
$1.35B
Trailing 12 months
Diluted EPS (TTM)
$299.86
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-4.24

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+793.0%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
272.8%
Debt / equity
—
Current ratio
13.5
EBITDA (TTM)
—
Free cash flow (TTM)
−$119.68M
Quick ratio
13.5
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$481.55M
Latest balance sheet
Cash & equivalents
$78.98M
Total assets
$496.31M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$119.17M
Capital expenditures (TTM)
$507,000
R&D (TTM)
$97.24M
SG&A (TTM)
—
Stock compensation (TTM)
$35.32M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
102
13F filer change QoQ
+22
Institutional ownership
79.1%
Conviction holders (share of 13F filers)
4.9%
Crowding (high-turnover and private-fund holders)
35.8%
Private-fund adviser ownership
34.6%
Active holders' share change QoQ
+5.1%
Holder tenure
7.7
Price vs estimated holder cost
-33.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
9.8%

Short interest

3 metrics
Short interest
12.2%
Latest settlement · 9.9 days to cover
Days to cover
9.9d
Short-squeeze score
66 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1817229 CUSIP 929033207 13F (30d) 70 filings 57 filers Visit website Investor relations